Premium
Viral oncolysate in the management of malignant melanoma. II. Clinical studies
Author(s) -
Murray Douglas R.,
Cassel William A.,
Torbin Arlene H.,
Olkowski Zbigniew L.,
Moore Melanie E.
Publication year - 1977
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197708)40:2<680::aid-cncr2820400214>3.0.co;2-#
Subject(s) - medicine , melanoma , immunostimulant , chemotherapy , lymph , disease , dermatology , pathology , immunology , cancer research , immune system
Melanoma cell oncolysate, prepared with Newcastle disease virus, was administered as an immunostimulant to 13 patients with metastatic melanoma. The oncolysate was well tolerated. Six treated patients evidenced a decrease in the size of skin nodules or diseased lymph nodes. Visceral lesions were not favorably influenced to any marked degree. One case of fulminating disease showed a change to slow progression and survived a year longer than was otherwise expected. Another patient, whose melanoma could not be controlled by surgery or chemotherapy, has been in complete remission for 2 years. It appears that viral oncolysate might be particularly helpful to patients with early disease. Cancer 40:680–686, 1977.